NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE107502 Query DataSets for GSE107502
Status Public on Nov 29, 2017
Title Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 (RNA-Seq)
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary LCCC1122 is a window trial in stage I-IV TNBC patients scheduled to undergo definitive surgery (either lumpectomy, mastectomy or surgical resection of oligometastatic disease). Enrolled patients will receive 1.5 -2.0 mg of the MEK1/MEK2 inhibitor GSK1120212 (trametinib; Mekinist®) orally once daily for 7 days (with treatment initiation dependent on surgical schedule) prior to their surgery, with pre- and post- treatment tissue analyzed for kinome response and resistant signatures. A single blood sample will be obtained for determination of plasma GSK1120212 concentration prior to surgery. Of note, the initiation of study treatment is defined by the surgical schedule; there will be no delays in standard treatment for the purposes of this study.
 
Overall design 28 samples representing 12 patients including pre-treatment needle core biopsies and post-treatment surgical resections

Raw data submitted to dbGaP (phs001405.v1.p1; https://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/gap) because of patient privacy concerns.
 
Contributor(s) Carey LA, Earp HS
Citation(s) 28108460
Submission date Nov 29, 2017
Last update date Mar 27, 2019
Contact name Gary L Johnson
E-mail(s) glj@med.unc.edu
Organization name University of North Carolina School of Medicine
Department Pharmacology
Lab Gary L. Johnson Lab
Street address 4009 Genetic Medicine Building, 120 Mason Farm Road
City Chapel Hill
State/province NC
ZIP/Postal code 27599
Country USA
 
Platforms (1)
GPL11154 Illumina HiSeq 2000 (Homo sapiens)
Samples (28)
GSM2869456 Patient 6 needle core biospy - pre treatment
GSM2869457 Patient 6 surgical resection - post treatment
GSM2869458 Patient 5 needle core biopsy - pre treatment_2
This SubSeries is part of SuperSeries:
GSE87424 Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex
Relations
BioProject PRJNA420378

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE107502_LCCC1122_DESeq2_trametinibresponse.txt.gz 743.4 Kb (ftp)(http) TXT
GSE107502_LCCC1122_normalizedLog2RSEM.txt.gz 1.3 Mb (ftp)(http) TXT
GSE107502_LCCC1122_rawRSEM.txt.gz 1.2 Mb (ftp)(http) TXT
Raw data provided as supplementary file
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap